Vanda Pharmaceuticals Tests NEREUS™ to Mitigate GLP-1 Drug Side Effects
Event summary
- Vanda Pharmaceuticals initiated Thetis study on April 8, 2026, evaluating NEREUS™ (tradipitant) for preventing vomiting in GLP-1 receptor agonist patients.
- The Phase 2 study showed a 50% relative reduction in vomiting with tradipitant vs. placebo in Wegovy® patients.
- Topline results from Thetis study expected by Q4 2026, with potential NDA approval requiring additional data.
The big picture
GLP-1 receptor agonists like semaglutide and tirzepatide have revolutionized diabetes and obesity treatment, but gastrointestinal side effects remain a barrier to adherence. Vanda's NEREUS™ represents a strategic play to improve tolerability, potentially expanding the addressable market for these therapies. The success of Thetis study could position Vanda as a key partner in mitigating side effects for next-generation GLP-1 drugs.
What we're watching
- Regulatory Pathway
- Whether Thetis study results will support a New Drug Application for NEREUS™ in GLP-1 induced vomiting prevention.
- Market Opportunity
- The pace at which Vanda can commercialize NEREUS™ if approved, given the growing use of high-dose GLP-1 agonists.
- Competitive Dynamics
- How Novo Nordisk and other GLP-1 drug makers may respond to potential solutions for side effect management.